EnquBio

Executive Summary

EnquBio is a San Diego-based preclinical contract research organization (CRO) founded in 2020, offering comprehensive drug discovery services including in vitro & in vivo pharmacology, immunology, HTS screening, CRISPR platforms, and biomarker discovery. As a service provider, EnquBio supports pharma and biotech companies in advancing their drug pipelines, capitalizing on the growing trend of outsourcing preclinical research. With a differentiated focus on integrated platforms like CRISPR gene editing and high-throughput screening, EnquBio is well-positioned to capture demand from emerging biotechs seeking efficient R&D solutions. The company's recent establishment and lean structure suggest potential for rapid growth, though it faces intense competition from established CROs. Management's ability to secure key partnerships and expand service offerings will be critical to achieving scale and profitability.

Upcoming Catalysts (preview)

• Q3 2026Expansion of CRISPR service offerings70% success
• Q4 2026Strategic partnership with a top-20 pharma company50% success
• Q2 2026Opening of a new laboratory facility to increase capacity80% success